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Abstract
Recently, the FDA issued new quality guidelines (Q10) encouraging drug manufacturers to
improve their quality monitoring procedures. This renewed focus on quality and risk
management has prompted Novartis to re-evaluate their systems and procedures to ensure
compliance with the proposed guidelines. The company has chosen to respond by introducing
more advanced statistical analysis of the data they share with regulatory bodies through the
Annual Product Review (APR). However, procedural changes alone cannot bring about the
needed innovation. Currently, too much time is spent on data consolidation and other non-value
added tasks allowing less time for analysis. The solution is an Information Technology system
with new procedures that will both improve process quality and increase productivity. The
design proposed in this thesis utilizes statistical software that can analyze data securely,
automatically generate graphs, and display alerts through an online dashboard. This Decision
Support System will be integrated into Novartis's Global APR Automation project which aims to
automate the generation of the entire APR document. A dashboard feature will allow processes
to be monitored continuously instead of annually. The final version of the system will also
include content management systems, business warehousing, audit validation and business
intelligence tools. In addition to software, alternate statistical methods are proposed for
evaluating critical processes that are either not in statistical control or lack normal distributions.
These methods together with the new IT tools should help Novartis address process exceptions
and reduce process variation without overloading the organization.
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1 Introduction
The pharmaceutical industry is known to be both capital intensive and highly regulated.
However, despite the vast amounts of money spent on drug development, and stringent oversight
by regulatory bodies, quality assurance monitoring is surprisingly primitive when compared with
other industries. Batch quality failures for the pharmaceutical industry range from 5 to 15% [2]
and waste has been reported to be as high as 50% [3]. In comparison, the semiconductor industry
maintains waste well below 1% [4]. The table below provides a more detailed comparison
between the two industries using a number of different quality metrics [1].
Sigma ppm Defects Yield Cost of Quality
__2a 308,537 69.2% 25-35%
MEMO 3 66,807 93.3% 20-25%
4a 6,210 99.4% 12-18%
5c 233 99.98% 4-8%
60 __3.4 99.99966% 1-3%
Figure 1. Quality Comparison between Industries
It is clear that the pharmaceutical sector has a long way to go before it can achieve the
type of quality control exhibited in the semiconductor industry. Even more troubling is the
problem of out of specification batches failing to be detected by quality assurance and ending up
in the hands of patients. A KPMG study reported that 72% of drug recalls are a result of
manufacturing defects [5]. There are two reasons that are often cited for this lack of innovation
in quality control tools.
1. High profit margins made increased investment in quality control tools unattractive.
2. Changes to manufacturing process require revalidation and extensive sampling which
makes it uneconomical to continuously improve them.
These assumptions are beginning to change. As the industry goes through a period of slower
growth and patent expirations, profit margins are beginning to decrease and quality costs will
become increasingly significant. Meanwhile regulatory agencies are attempting to work with
pharmaceutical firms to develop frameworks that allow more room for innovation.
1.1 Thesis Structure
Chapter 1 introduces the challenges facing the pharmaceutical industry in terms of quality
control which provides the motivation for the thesis. The main objective of the thesis is
described as well as a breakdown of the various research components. Chapter 2 gives a detailed
background concerning the new regulatory guidelines issued by the FDA and their affect on the
Annual Product Review document. The current Novartis procedure for statistical process control
is presented along with its shortcomings. Chapter 3 provides a brief overview of some common
statistical process control techniques as well as the key assumptions behind them. Chapter 4 is
the data analysis section. It introduces the three quality parameters that have been collected for
and describes the method for sampling and analyzing them. The data for each of these
parameters is presented and underlying statistical problems are discussed. The chapter concludes
with recommendations for how to best analyze these attributes and present them in a coherent
and appropriate manner for the APR report. Chapter 5 is the IT section of the thesis. It describes
the underlying enterprise architecture for the Quality Assurance group and the various systems
that will make up the new Decision Support System. The chapter also describes the criteria for
software evaluation and an explanation for the final software decision. Chapter 6 is a Three Lens
analysis that highlights some of the organizational changes needed to fully utilize the new
software tool. It highlights some of the cultural diversities between various groups at Novartis
and how these may impact system implementation. Finally, Chapter 7 presents the conclusion of
the thesis and next steps for the project.
1.2 Project Motivation
In an effort to spur pharmaceutical manufacturers to improve product quality and obtain
better control over their manufacturing processes, the FDA in 2009 issued an industry guidance
titled Q10 Pharmaceutical Quality System. The guidance describes a "pharmaceutical quality
system to enhance the quality and availability of medicines" [7]. One of its key objectives is to
encourage manufacturers to "develop and use effective monitoring and control systems for
process performance and product quality, thereby providing assurance of continued suitability
and capability of processes" [7]. The guidance impacts a number of areas including regulatory
filings drug manufacturers must produce each year such as the Annual Product Review (required
for compliance in the U.S) and the Product Quality Review (required for compliance in the E.U).
Every manufactured drug must have these reviews submitted periodically in order to meet
regulatory compliance (and continue producing the drug). The Ql0 guidelines affect these
reviews because it suggestsI manufacturers should now provide statistical analysis of parameters
critical to the production process. The motivation behind this is to help manufacturers identify
problems early, identify their root cause and take actions to prevent the problems from occurring
in the future. The current system in place for performing these tasks can be improved so that it is
better suited to meet these requirements. For example, the overall process for generating the APR
report lacks an audit trail which can create data security issues. The structure of the databases
also leads to large amounts of time to be spent on data consolidation instead of data analysis.
Therefore a new system is required to correct these issues, and improve productivity.
1.3 Objective
This thesis proposes a framework for a Decision Support System (DSS) comprised of a
backbone IT infrastrucutre and business intelligence tools that will help meet the quality system
guidelines proposed above. The tool will automatically generate charts, tables, graphs for
particular sections of the APR/PQR report, provide continuous monitoring of critical process
parameters, alert users to outliers and trends which lead to deviations (using a dashboard) and
provide a basis for assessing process capability when possible. Specific analytical methods are
proposed for the three critical process parameters studied as part of the research.
1.4 Novartis Pharmaceuticals
The recommendations proposed in this thesis have been specifically designed for Novartis
Pharmaceuticals, a division of Novartis A.G based in Basel, Switzerland. The research described
in this thesis is the result of a six month internship with Quality Assurance & Compliance
division within the Technical Operations Group. Research and data was gathered primarily from
the Novartis manufacturing plant located in Stein, Switzerland. The Stein facility is the largest
production plant within Novartis Pharmaceuticals. It is also a "Center of Excellence" which is a
designation Novartis grants to plants that specialize is a certain area. Stein specializes in
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead,
guidance describes the Agency's current thinking on a topic and should be viewed only as a recommendation.
launching new drug products [5]. Almost all new Novartis drugs are first manufactured on a
commercial scale at the Stein plant. During this initial campaign, the manufacturing process is
fine tuned and any bottlenecks in the developmental stage are addressed to ensure high
efficiencies and quality. Stein's role as a launch site for new drugs, means it is both a high
throughput plant for blockbuster drugs, and a low volume, high mix plant (LVHM) for newer
drugs. This complicates the design of automated tools because the high mix of drugs means the
software tool must be able to handle many different data types. Shorter campaigns for new drugs
also yield fewer data points which create issues when assessing process capability and stability.
Therefore the quality assurance monitoring system must be robust enough to handle different
production environments if it is to be successfully deployed.
1.5 Global APR/PQR Automation Project Integration
In June 2010, Novartis Pharmaceuticals approved a project to build a software tool to
automate the generation of the entire APR/PQR report. The APR/PQR report consists of several
chapters relating to various aspects of the drug manufacturing process (see Chapter 2 for detailed
explanation). For the APR/PQR automation project to be a success, the tool must be able to
automatically generate chart and graphs along with related capability indices. Two individuals
head up the automation project team. One is responsible for representing the business needs
while the other is responsible for IT project management. Both these individuals periodically
report back to a steering committee that approves incremental funding and major project
decisions such as selection of software vendors and changes to the project scope. Since statistical
analysis is required for both the APR/PQR report and meeting the objectives of the Q10 Quality
System guidelines, it has been proposed that the statistical platform and related online dashboard
become part of the approved automation project. The steering committee recently approved the
proposal. The decision means that the proposed statistical platform will eventually be deployed
globally to all pharmaceutical manufacturing sites.
2 Background
This chapter begins with a background on the APR/PQR document and its objectives in
terms of regulatory compliance. Aspects of the APR/PQR that are relevant to the thesis are
highlighted. The chapter then describes current procedures for quality control and Good
Manufacturing Practice (GMP) compliance at Novartis. The final section describes in detail the
need for an updated decision support system.
2.1 Regulatory Compliance and the APR/PQR
Unlike the production of most other products such as microchips or clothes,
pharmaceutical drugs are highly regulated by the governments of the countries in which they are
sold due to their sensitive nature. In the United States, pharmaceutical drug manufacturing is
governed by the Good Manufacturing Practice (GMP) guidelines which are enforced by the
FDA, under Section 501(B) of the 1938 Food, Drug, and Cosmetic Act. GMP guidelines must be
adhered to strictly and regulatory agencies reserve the right to inspect any drug production site
they chose without prior notice in order to ensure compliance. As part of these guidelines, the
FDA requires an annual review known as Product Annual Review (PAR) also referred to as the
Annual Product Review (APR). The purpose of this proposed GMP requirement is to provide a
mechanism for both the regulatory agency and drug manufacturer to review the quality standards
for each drug product manufactured. In 2001, the FDA adopted and published the guidance for
industry Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
[1]. While the guidance was formally issued by the FDA, it was developed within the "Expert
Working Group (Quality) of the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH)." The guidance has
been endorsed by the ICH Steering Committee and adopted by the regulatory bodies of the
European Union, Japan, and the United States [7].
In the European Union, the EMEA is the regulatory body responsible for coordinating the
scientific evaluation of the safety, efficacy, and quality of medicinal products. The EU GMP
Guide is the document that provides the details supporting the principles of GMPs within the EU.
In 2004, EMEA made available a draft revision of the EU GMP Guide proposing, for the first
time, a requirement for a Product Quality Review. The Product Quality Review (PQR) has the
same objectives as the APR and its structure is similar to the APR. A comparison of objectives
between the two regulatory reports is shown in Figure 2.
Identify pr:duct and process Not specified Required Not specifiedimnpr %,eients
Identify crt a cftion npected Required RequiredI-t specified
CFR denotes Code c!Fdea) R o EG denotes European Cornrnision, and IcH denotes
International Conte rence on Harmonization.
Figure 2. Comparison of Objectives between APR and PQR [8]
In order to ease the regulatory burdens, many manufacturers adopt the APR/PQR report
which serves to meet the requirements of both reports. In essence, the APR/PQR is an annual
retrospective revalidation of the manufacturing process. The procedures for performing a typical
APR/PQR involve the review, analysis, and trending of historical data (i.e., data generated in the
past 12 months), which fit the definition of retrospective process validation as defined in the
FDA's validation guideline and the EU GMP Guide Annex 15 on qualification and validation (5,
6). Because the process of consolidating data and performing statistical analysis is both
computationally intensive and repetitive, Novartis has proposed that the process can be highly
automated through the development of new processes and better integrated software.
2.1.1 Process Validation
When a new drug product is introduced in a manufacturing plant and scaled up for
commercial sale, the production process must be validated to ensure it meets the requirements
stated in the initial regulatory filing. The initial validation is based on three trial run batches and
once these batches are shown to be within the specification, the process is validated and
essentially locked in that form. Subsequent process changes are difficult. Anytime a change is
requested to make a process more efficient, a manufacturer must file data and documents
verifying that the new process does not impact product quality [9]. The APR/PQR must
document all process changes and show the effect (if any) these have on the quality of the drug.
2.1.2 CAPA
In addition to aiding with process validation, the APR/PQR contains sections that can
help identify trends and assist with Corrective and Preventative Actions (CAPA). CAPA is a
concept within GMP that focuses on indentifying deviations and failures, investigating their
"root cause" and taking preventative actions to ensure these sources of variation are eliminated in
future batches.
2.2 Quality System Guidance Objectives
The purpose behind this project is to support Novartis so they can meet the guidelines set
forth by the FDA in the Q10 Quality Systems guidance. While the Q1O guidelines contain a
number of goals, the project focuses on targeting the following specific Q10 objectives [7]:
* Participate in the design, implementation and monitoring of the pharmaceutical quality
system.
" Demonstrate strong and visible support for the pharmaceutical quality system and ensure
its implementation throughout their organization.
* Key performance indicators should be identified and used to monitor the effectiveness of
processes within the pharmaceutical quality system as described in Section 4 of the QlO
Guidelines.
The system developed as part of this project will allow production and Quality Assurance to
meet these objectives in a time frame much faster than currently possible. The productivity gains
will allow staff to spend more time investigating deviations and improving the process instead of
gathering and analyzing data.
2.3 Current Quality Assurance Procedures
The current procedures for quality monitoring at Stein can be broken down into two
categories. The first category governs the sampling, testing and data entry procedures that are
part of the QA/QC technician's daily report. The second category governs the procedure for
generating the APR/PQR reports. APR/PQR reports are compiled by the QA/Compliance
department according to the quality directive written by the Global Quality Assurance
department which must comply with GMP guidelines. The procedure for the trending of the
predefined quality attributes was written by the Novartis IQP team and is described in Section
3.1, Chapter 2.
2.3.1 Process Map for Product Sampling and Testing
Finished product is randomly sampled from a production batch for a particular drug and
delivered to the Quality Control lab2. Depending on whether the drug is packaged in a solid or
liquid form, it is directed to a particular QA/QC lab. Lab technicians perform a variety of tests
not only on the finished product, but also on the incoming raw material and active ingredients.
The types of tests and the procedures for these tests will be described in Chapter 4. The data
from these tests are automatically uploaded into a software package called Chromeleon. Any
2 Batches are sampled to ensure independence.
data points outside the internal specification limits for the drug (referred to as out of expectation
or OOE) are highlighted. Samples are re-tested depending on the procedures of the particular
test. Chromeleon also computes a number of other relevant values for the sample batch including
the min, max, mean and standard deviation values. Lab technicians then manually enter them
into the SAP Quality Management (QM) database. Individual values are not copied to SAP at the
moment.
2.3.2 IQP and the Current Procedure for APR/PQR
The Innovation Quality Productivity (IQP) group is an internal Novartis team that works with
manufacturing, quality assurance and other stakeholders to introduce lean manufacturing and six-
sigma practices. While the guidelines governing the overall APR/PQR report are documented in
the global Novartis Pharma Directive, the section on Analytical Results is guided by procedures
issues by IQP. The IQP team wrote the Standard Operating Procedure (SOP) for performing
Process Capability Analysis using Minitab@ Statistical Software [12]. The document "details the
procedure to follow for the calculation and the statistical analysis of the process capability, using
the Minitab@ Statistical Software." Process capability is one of the main statistics Novartis lists
in the Analytical Results section to indicate the performance of a particular process. The
procedure for calculating process capability according to the SOP is summarized below.
1) Lab technicians must create a MS Excel spreadsheet with all testing monograph data
compiled from various databases including SAP QM.
2) Minitab Statistical Software is then opened, and the excel spreadsheet data is copied and
pasted into a Minitab worksheet (check for data integrity).
3) The Capability Six Pack Analysis (located under Quality Tools) is used to create a run
chart, distribution chart, and the process capability statistics for a particular data set.
4) The excel spreadsheet and the Minitab file is then e-mailed to QA/CPL personnel that
will be completing the Analytical Results section of the APR/PQR. Discussions with
production and QA/QC are necessary for the interpretation of the data.
5) The graphs are copied and pasted into a MS Office Word document and then e-mailed to
other parties who will work on subsequent sections of the document.
There are several major flaws with the current procedure.
* Consolidating data from various databases into an excel spreadsheet is time consuming
(often taking more than three hours). It is non-value added since it simply involves
replicating data already gathered. This reduces the amount of time personnel can spend
on root cause investigations.
* All the data transfers between SAP QM, Excel, and Minitab are unsecure. This means
data can accidentally be modified with no method of verifying data integrity. Data
integrity is a required component of compliance. For example, if regulatory audits show
discrepancies between data submitted on the APR/PQR and actual data collected, it could
lead to major penalties.
e There is no secure audit trail for the APR/PQR document as it is assembled. This makes
it difficult to track changes.
e The procedure does not provide much information on how to handle data sets that do not
yield themselves to process capability assessment. Process Capability analysis requires
data to be normally distributed and statistically stable. Yet there are many instances
where one or neither of these requirements is possible. Alternate methods must be
suggested for handling these data sets.
3 Statistical Process Control Basics
In this chapter, we will analyze statistical process control techniques as well as the current
Novartis procedure for statistical charts and process performance. We will also analyze the
underlying assumptions for control charts and process capability. This will have significant
implications of the data sets discussed in Chapter 4.
3.1 Statistical Process Control
The use of Statistical Process Control in manufacturing goes back to the 1920s when
William Shewhart (then at Bell Labs) first pioneered the use of control charts and other
mathematical methods to improve the quality of telephones manufactured at the time [13]. Since
then, numerous experts in both industry and academia have contributed to the field through more
advanced techniques and methodologies. At its core, SPC consists of a set of techniques that
quantify the variation within a manufacturing process and help users determine whether the
variation is natural to the process or requires further investigation. The physical benefit of such a
system is that it can help predict manufacturing problems before they physically manifest
themselves as defects. The Novartis IQP group has adopted several SPC principles into the
procedure for statistical analysis in the APR/PQR.
3.2 Chart Types
There are many different types of charts that can be used to analyze process data. A brief
overview of common chart types is provided below.
3.2.1 Acceptance Chart
The simplest of all statistical charts, the acceptance chart simply graphs the sample data,
provides the sample mean, and the customer specification limits for the process. The chart
provides a visual method for ensuring data is within specification and not out of compliance.
While the chart provides no information about process variation (and capability) it can help
identify trends and potential problems in a qualitative sense.
3.2.2 X Chart and Process Control
The X chart also known as a X control chart is a graphical display for a quality
characteristic that has been measured. If the data points represent sample averages, then X is
used to monitor the process mean. The chart contains a center line and an upper control limit line
(UCL) as well as a lower control limit line (LCL). Typically, a process is assumed to be in-
control, if all the sample data falls between the UCL and LCL. The UCL and LCL are typically
calculated using the center line and the sample standard deviation. Typically, pt (the mean of the
sample statistic w) is used for the center line and aw (the standard deviation of the sample
statistic) is used to calculate the UCL and LCL. If a process is deemed to be within six-sigma,
then all the sample values must fall between +3o, and - 3cw. More generally
Upper Control Line = pw + Low
Center Line = pw
Lower Comtrol Line = pw - Law
where L is the distance from the control limits to the center line.
In Minitab, data points that fall outside these control limits are highlighted in red,
indicating they are outliers. Outliers can also exist inside the control limits depending on the user
defined rules. Novartis IQP has chosen four tests to determine if a data point is in control. These
four rules are defined in Minitab and given below:
1. One point is more than three standard deviations from center line (outside of control limits).
2. Nine points in a row on the same side of the center line.
3. Six points in a row all increasing or decreasing.
4. Fourteen points in a row all alternating .
Rules 2-4 help identify non-random patterns that may be caused by underlying process
issues. For example, nine points in a row on the same side may indicate that the process is
beginning to drift in a particular direction. Action must be taken to determine the root cause.
3.3 Process Capability
Process capability refers to the uniformity of the process and is an integral part of six
sigma analysis. It allows the user to measure the variability in a process using both the mean and
the standard deviation of the sample data. Process capability can be assessed with or without
regard to the process specifications. Major uses for the data gathered through process capability
analysis include the following [13]:
" Predicting how well the process will hold the tolerances.
" Assisting process experts in modifying the process.
" Assisting in establishing the interval between sampling for process monitoring.
* Specifying the performance requirements for new equipment.
* Reducing the variability in a manufacturing process.
Process capability ratios provide a quantitative way to express process performance.
USL -
Pru = 30-
- LSL
3-
USL
+3ar
x
Natural variation of the process
Customer specincation width
Figure 3. Histogram with Control Limits
The ratio Cp does not account for whether the mean of the sample data is centered
between the control limits. It only measures the spread of the specifications relative to the six-
sigma spread of the process. To account for the centering of a process, the term Cpk is defined as
the minimum of Cpu and Cpl. The difference in magnitude between C, and Cpk indicates how well
the process is centered. If the two terms are equal then the process is perfectly centered between
the upper and lower specification limit. The term C, is therefore referred to as process capability
and the term Cpk is referred to as actual capability.
3.3.1 Independence
In order to use control charts effectively, it is assumed that data sets are independently
distributed. If the quality characteristics represent even low levels of positive correlation, control
charts will give misleading results in the form of too many false alarms [13]. When we consider
the Novartis manufacturing processes we must be careful to ensure that independence of
observations is maintained. Sampling procedures currently in place help ensure that the samples
- 3cy
are representative of the batch. Autocorrelation of the data over an annual period shows fairly
low autocorrelation, indicating that the process appears to be stochastic.
3.3.2 Assumptions for Process Capability
There are two critical assumptions for process capability calculations. One is the assumption
that the underlying process produces a normal distribution of values. The other assumption is
that the process is in statistical process control. Testing for normal distribution can be performed
using a normal probability plot. If the plot fails to yield a nearly straight line then we can reject
the hypothesis (with some confidence level) that the underlying data is normal. For a process to
be in-control, the data points must fall between the three sigma limits, with a corresponding
expected false alarm rate. Furthermore, process capability is attempting to measure variance due
to natural causes so all excursions with known root causes (such as a non-calibrated machine)
must be excluded from the calculation. If either of these assumptions is violated, then the
estimates for process capability ratios (based on sample data) may not accurately reflect the
underlying process. This is a key issue for the data sets analyzed in this thesis, and in Chapter 4
we will investigate methods for handling data sets that violate these assumptions.
4 Data Analysis
Quality Assurance/ Quality Control is responsible for performing a number of tests on drug
products. However, the APR/PQR only requires manufacturers to provide process data for
metrics deemed as "critical parameters". It is therefore up to each firm to decide which
parameters are critical for a particular product. For the purposes of this project, it was important
to narrow down the field to a few parameters and determine the best way to analyze these data
sets using new methodologies. The parameters chosen for this task are dissolution, assay and
content uniformity. These are critical parameters for products produced by the solids department.
These parameters will be described in the sections below.
4.1 Dissolution
Dissolution refers to the rate at which a tablet or capsule dissolves. This is an important
parameter for solids because the rate of dissolution reflects the rate of the active ingredient which
is available for later absorption in the blood stream. Every solid drug product (typically a tablet
or capsule) has a Q value which refers to the amount of active ingredient that must be dissolved
within a specified time. The U.S Pharmacopeia has strict guidelines for performing the
dissolution test [14]. The test involves placing a sample in a lab apparatus with a solvent that
simulates the dissolution of active ingredients in the blood stream. Careful attention must be paid
to the pH of the solvent, the temperature and other factors to ensure that the tests are accurate.
There are also separate methods for immediate release dosage and extended release dosage
forms. An acceptance table (shown below) explains how samples are tested and measured. If the
samples fail stage 1, there are two additional opportunities for the batch to pass. Essentially each
stage takes a wider set of samples and relaxes the threshold for compliance.
Stage Number Tested Acceptance Criteria
Si 6 Each unit is not less than Q + 5%
S2  6 Average of 12 units (SI + S2) is equal to or greater than Q, and no unit is
less than Q - 15%
S3  12 Average of 24 units (S1 + S2+ S3) is equal to or greater than Q, not more
than 2 units are less than Q - 15%, and no unit is less than Q - 25%.
Figure 4. Acceptance Table for Dissolution [15]
To perform the dissolution test, six samples are initially chosen and tested. After a
specified time, the percentage of dissolved active ingredient is measured for each sample, and
these percentages must be no less than 5% of the stated Q value. If any samples fail this test,
there are similar requirements for stage 2 and stage 3 with additional samples. Ideally, we would
like all the individual values to be stored in the database for use in the statistical analysis.
Unfortunately, in the current set-up, only the minima values are stored.
4.2 Assay
The assay test is performed to determine the amount of active ingredient in a tablet or
capsule and ensure that it is in compliance with the drug label [17]. The measure is typically
reported as a percentage. The assay can also be thought of as the dosage strength or potency of a
drug. The quantity that refers to 100% is set to a finite value so it is possible to have values
greater than 100. Determining what the appropriate compliance limits for assay should be is
difficult because of drug stability issues. For example suppose a label states that the amount of
active ingredient in a tablet should be 95% of the stated active ingredient weight. When a batch
of these tablets is initially produced, a sample might show it is 100%, which is well within the
95% compliance. However, it is known that many active ingredients degrade over time through a
variety of processes including hydrolysis and oxidation [18]. Therefore, after a year on the shelf,
this same tablet might only have 90% of the stated active ingredient and could be out of
specification with the label. Incidentally, this is why most drugs have an expiry date. Drug
stability is a major issue for manufacturers because it is difficult to simulate several years of
shelf life in the lab. Pharmaceutical firms must continue to sample batches many years after they
are produced and if the amount of active ingredient falls below a threshold, the batch must be
recalled. Therefore the internal release limits for assay are based on the corresponding stability
tests to ensure active ingredient content remains within the customer specifications for the shelf
life of the drug.
4.3 Content Uniformity
Content uniformity (also referred to as Uniformity of Dosage Unit) is defined as the degree
of uniformity in the amount of drug substance among dosage units [16]. The test is performed to
ensure the consistency of dosage units (for example tablets) and ensure that the drug substance
content for each tablet in a batch is within a narrow range around the label content. In essence, it
is a statistical test performed on the assays to ensure that there are no significant deviations
among the samples in a batch. The U.S Pharmacopeia describes in detail the statistical
calculations for determining the acceptance value for content uniformity based on the assay
values for individual batch samples [16].
Acceptance Value (AV) is defined as
AV = IM - XI+ ks
The variables in the acceptance value calculation can be summarized as follows.
In this equation, the X variable is the mean of the individual sample assay values expressed as a
percentage of the label claim. M is a reference value that can either take on the value X, 98.5%,
or an arbitrary target value for assay depending on the range for X. Typically the target value for
the assay is 100% but this can change depending on other factors (such as drug stability). The
variable k is an acceptability constant that is either 2.4 or 2.0 depending on the sample size.
Finally s is the sample standard deviation.
n-S [(I - X)21
n - 1
The term LI is defined as the maximum allowed acceptance value. Unless otherwise specified,
U.S Pharmacopeia defines Li to be equal to 15.0. The typical sample size for the uniformity of
dosage test is 10.
4.4 Data Analysis Issues
As stated in Chapter 2, the main goal of both the internal Novartis process capability
guidelines and statistical process control is to be able to assess to the performance of a process
and detect problems before they manifest themselves. Using Minitab and the Novartis Process
Capability SOP, process capability for a number of attributes have been calculated and are
shown below. Recall that the two requirements for calculating process capability are that the
process must be statistically stable, and the data set under analysis must be normally distributed.
Figure 5. Capability Plot of CU Acceptance Values
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4.4.1 Process Stability
Viewing the graphs shown above, it is clear that all of them fail the test for process
stability. Process stability (as defined in the internal SOP) requires the presence of zero red data
points in a chart. In fact a more comprehensive analysis of several data sets from numerous
products and attributes reveals almost all data sets when viewed on an annual basis are
statistically unstable. Shortening the time frames can improve stability but not substantially.
4.4.2 Normal Distribution
Statistical tools such as process capability and even charts such as the X chart (which
show the ±3 sigma limits) require the data displayed to be normally distributed. Normally
distributed data can be solely described by the arithmetic mean t and the standard deviation C.
These parameters can be estimated by the sample mean (X) and sample standard deviation s,
respectively. The Central Limit Theorem tells us that the sample size is sufficiently large, then
the mean of a random sample from a population has a sampling distribution that is approximately
normal, regardless of the shape of the distribution of the population [13]. However, there is no
magical number of samples at which point we can declare the data to be sufficiently normal.
Furthermore, not all critical parameters use samples means (content uniformity uses a different
measure called acceptance value). Process changes can also cause instability in the data and
make it harder to obtain a normal distribution. Therefore even though the Central Limit Theorem
should in theory guarantee a normally distributed data set, the sample size and the other factors
described make it difficult to achieve normality in practice. As described in Chapter 3, without a
normal distribution, many of the methods discussed for analyzing process capability and control
limits fail. Viewing the probability plots in the graphs above, reveals the lack of normal
distribution for many data sets. Minitab uses a p-value of 0.05 to gauge whether the data follows
a normal distribution3 but most data sets fail to show normal distribution regardless of how
normality is measured. Adjustment of the time frame can help in obtaining a normally distributed
data set but there is no guarantee of this [30].
4.4.3 Independence
Data sets must be tested for auto-correlation to ensure independence. If sample averages
are used to represent each batch, we must ensure that successive sample averages are not being
3 There is no universal minimum p-value which determines normality. Generally lower p-values indicate that the
distribution is more likely to have been sampled from a normal distribution.
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calculated from the same batch. In cases where batches are re-sampled (additional samples are
drawn from the same batch), the data has to be modified to ensure that both the old and new
sample data points are excluded. With the exception of a few short data sets that showed high
auto-correlation, most data sets showed independence. Short data sets in general are problematic
for a number of reasons described later in this chapter.
4.4.4 Time Frame
It is important to note the time frames for the data sets in the graphs. There is currently no
active continuous monitoring of quality data, and investigations are only triggered if a drug batch
fails to meet the criteria stated on the testing monograph. The red points represent data points
that are in violation of one or more of the four statistical tests included in the SOP. However,
since no statistical evaluation is performed during the period, these points are rarely investigated
unless they happen to fall outside of the internal release limits or the customer specifications.
Furthermore, the ±3- upper and lower bounds are not actually used in daily practice. Therefore
the prevalence of outliers or trends is not surprising. Since there is no monitoring of data based
on the guidelines in the SOP, the only method for investigating outliers or trends is to
retroactively search the process change record and the database which contains root cause
investigations, to look for potential shifts in the data due to material changes or process changes.
This retroactive look at data can be misleading because it is not always obvious whether a
documented physical change actually caused a change in the data. Unfortunately without active
real-time monitoring this is the only available method. Splitting data sets into smaller segments
based on physical changes in the process (such as new equipment or a new raw material supplier)
can improve both process stability and normality. This bodes well for the online statistical
platform proposed in this thesis since it will help in both these areas. However, this brings up
some important issues that must be determined prior to implementation of the online system. Are
statistical stability and normality absolutely necessary to assess process performance? Are
control limits based on ±3 standard deviations from the mean appropriate with these data sets?
Resolving these questions is important for overall success because despite new sophisticated
software tools and near real-time automated analysis, the data will remain the same.
4.5 Resolving Non-Normally Distributed Data
Most charts including X charts and process capability calculations require data to be
normally distributed. The symmetric control limits seen on charts results from the assumption of
normality. In the case of highly skewed distributions, a typical X chart would provide very
misleading results [20][21]. As stated previously an X chart is an ongoing test of the hypothesis
that the process is operating in a state of statistical control [19]. If a symmetrical X chart is used
for a data set that has a skewed distribution, the probability of both a Type I error and a Type II
error will be different from those which are typically associated with a X chart. For example, if a
process is within six- sigma, the a-risk (the risk of committing a Type I error and concluding that
the process is out of control when in fact it is stable) is 0.0027. However, if the actual
distribution of the sample values is not normal, the risk could be much higher. Borror,
Montgomery and Runger [22] studied the behavior of the Shewhart control chart for process data
that is not normal. They concluded that even if the process shows evidence of moderate
departure from normality, the control limits given here may be entirely inappropriate [13].
4.6 Reasons for Non-Normal Data
In this section we will cover some of the reasons why a data set may not be modeled using a
normal or Gaussian distribution.
4.6.1 Data is close to zero or a natural limit
A data set may be skewed towards one side of the mean because a natural process limit
exists. For example zero is often the natural process limit when describing cycle times and lead
times. Since time cannot be negative, a distribution may have a large number of points close to
zero and a long tail to the right as shown in Figure 8.
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Figure 8. Example of Non-Normality due Natural Limit at Zero [10)
4.6.2 Extreme Values
Some data sets will appear to have a skewed distribution due to too many outliers that are
far from the mean. It is possible to fix this problem be reanalyzing the data and removing outliers
that have a known root cause. As discussed in the section on normal distribution, small
percentage of extreme values should be expected, so only points with known explanations can be
removed.
4.6.3 Multimodal Distribution
Process data distribution may appear to be non-normal because it is actually the
combination of two or more different processes. These data sources may be normally distributed
on their own but when overlapped the combined data may look bimodal or multimodal. For
example, two pH testers in a lab may not be calibrated using the same solution. Therefore each
tester may produce data that is normally distributed but the mean pH from one tester may be
different from the other tester. The result will be the superposition of two normal distributions
with different means.
4.6.4 Data Shifts
Other potential reasons for not obtaining a normal distribution revolve around significant
shifts in the data. A time series plot that shows large shifts in data or seasonal fluctuations will
lead to a bi-modal distribution and or a large variance. If these shifts can be identified, the data
should be split into two sets and analyzed separately.
4.6.5 Individual Values vs. Average Values
All the values used for dissolution and assay are average values from batch samples. If the
individual samples come from a batch that should be normally distributed, then the averages
across batches should in theory also produce a normal distribution [13]. Therefore the use of
average values rather than individual values should not cause non-normal distributions as long as
the number of samples is sufficiently large. With the new statistical platform proposed in
Chapter 5, analysis can be performed on both individual values as well as average values.
4.7 Methods for Handling Non-Normal Distributions
There are numerous methods for handling non-normally distributed data. Identifying a
mathematical distribution can help to develop alternate control limits. Many software packages
today (including Minitab) have algorithms to help identify whether data belongs to a particular
class of distributions. If a data set fails to fit a particular distribution, various mathematical
transformations can be applied to obtain a normal distribution. Another method can be to analyze
a histogram of the data and use percentiles to set control limits. All these methods are analyzed
below. It is important to note here that charts based on samples from a non-normal distribution
will have asymmetrical control limits [23].
4.8 Transformations
As stated earlier, non-normally distributed data poses a number of problems for statistical
analysis. Over the years a number of mathematical transformations have been developed to
overcome this problem. Transforming data means performing the same mathematical operation
on each piece of original data. A common example of a transformation is converting miles into
kilometers by multiplying the data by a constant (in this case 1.609). This type of transformation
is known as a linear transformation because it scales the data but will not change the overall
shape of the data distribution. In linear transformations, data is simply multiplied or divided by a
specific coefficient or a constant is subtracted or added. Since the actual shape of the distribution
remains unchanged, linear transformations are not very useful for helping data look more
normal. A more useful transformation to achieve normality is the Box-Cox transformation.
4.8.1 Box-Cox Transform
The Box-Cox transformation is a procedure that helps identify the optimal power
transformation for achieving normal distribution. A power transformation involves raising all
data to the power of lambda. For example, if all data points are squared then lambda will equal 2.
In 1964, statisticians George Box and David Cox developed a procedure to identify an
appropriate exponent (lambda) to use to transform data into a "normal shape" [24]. The Box-Cox
algorithm searches for the optimal lambda (between -5 and +5) that will transform the data into a
normal distribution. However, there is no guarantee that the optimal lambda will produce a
normal distribution. Once the optimal lambda is selected (one that is most likely to yield normal
distribution), the transform must be applied to the data set, and probability plot must be
performed.
The Box-Cox transformation is defined by the following piece-wise function:
fXA - 1\
x(A) =( A 0
x() = ln (x) A = 0
At X=O, the function would produce a singularity since any value raised to the power of zero
yields a value of 1. By defining a separate equation at k=O, x(A) becomes a continuous function.
There are several methods for obtaining an optimal lambda such as finding the lambda
that maximizes the log-likelihood function. However, the most straightforward approach is to
choose a lambda for the Box-Cox linearity plot so that it maximizes the correlation between the
transformed x-values and the y-values when making a normal probability plot of the transformed
data. Though this brute force method is more CPU intensive, today's computers can easily
handle this method even with large data sets. The output from this method will also yield the p
value for the optimal lambda and indicate whether Box-Cox transformations are appropriate for a
given data set.
4.8.2 I-Charts and 3 Sigma Limits using Transforms
The Capability Plots in the Quality Toolkit for Minitab allows the user to automatically
apply Box-Cox transformations to data sets. The software automatically determines the optimal
lambda (between -5 and 5), applies the transform, and graphs the data. Since the normal
probability plot is included, the user can clearly see whether the transform was successful in
making the data more normal. The major issue with using transforms (including Box-Cox) is that
most users have trouble making sense of the data. See the example below, which shows data
collected for a particular QA attribute.
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Figure 9. Capability Plot for QA Attribute With Non-Normal Distribution
Though the histogram gives the impression that the data has a bell shape, the normal
probability plot indicates that the data is not normal. Visually the data appears to be non-linear
on the plot, and the p-value for the plot is less than 0.005. Without a normal distribution the
capability statistics (i.e., standard deviation, process capability) do not carry any meaning. If we
use a Box-Cox transformation, the optimal lambda is determined to be 0. This is a natural log
transformation.
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Figure 10. Capability Plot of Data with Box-Cox Transformation
The graphs for the transformed data are shown in Figure 10. The normal probability plot
shows a fairly linear plot and a p value of 0.0484. The capability histogram uses the transformed
data. The USL or upper specification limit has also been transformed as ln(10) = 2.309. The I-
Chart and moving range chart are also in the transformed domain. This can be jarring because
the numbers have no connection the actual physical process. Conceptualizing the natural log of a
measurement can be challenging. To make sense of these charts, the UCL and LCL limits need
to be transformed back into the original values. Since A = 0, the inverse natural log will
transform values back to the original domain.
UCLoriginal = e 1981 ~ 7.2
These values can be used to establish the six sigma limits for the original data. A run chart with
these values and the customer specifications is shown below. The UCL value now makes sense
4 Typically a p-value of 0.05 is used as a threshold to determine whether data is normal. In this case 0.048 is very
close to this threshold value and we have considered the data to be sufficiently normal.
since it is in the same domain as the original data. These statistical control limits could serve as
the internal control limits for this process. Any points outside these control limits would cause an
excursion and require a root cause investigation.
Figure 11. Control Chart with Assymetrical Control Limits5
4.8.3 Johnson Transform
Another powerful transform that can help produce normal distributions from non-normal data
sets is the Johnson transformation [33]. The transform is named for Norman L. Johnson who in
1949 provided a system of transformations to transform non-normal data to a normal form. The
Johnson system is comprised of three curves, Bounded, Log-Normal, and Unbounded. The
method by which the algorithm estimates the optimal curve for a given distribution is beyond the
scope of this thesis [25] [26]. Modern software packages have no trouble performing Johnson
curve fitting, and Johnson transformations are included in the Minitab software package. Using
this class of transforms we were able to transform eighty percent of analyzed data sets into
approximations of the normal distribution. It is therefore more powerful than the Box-Cox
transformation but can used in an identical manner.
s Ignore the lower limit of 1.3 in this chart. It is a result of another analysis and does not reflect the transformation.
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4.8.4 Non-Normal Process Capability Indices (Percentile Method)
As described earlier, process capability indices are generally computed to evaluate the
quality of a process, that is, to estimate the relative range of the items manufactured by the
process (process width) with regard to the engineering specifications. For the standard, normal-
distribution-based, process capability indices, the process width is typically defined as six-sigma,
that is, as + three times the estimated process standard deviation. For the standard normal curve,
these limits (z, = -3 and zu = +3) translate into the 0.135 percentile and 99.865 percentile,
respectively. In the non-normal case, the three sigma limits as well as the mean (zM = 0.0) can be
replaced by the corresponding standard values, given the same percentiles, under the non-normal
curve [27] .
Shown below are the formulas for the non-normal process capability indices:
Cp = (USL-LSL)/(Up-Lp)
CpL = (M-LSL)/(M-Lp)
Cpu = (USL-M)/(Up-M)
Cpk = Min(Cpu, CPL)
In these equations, M represents the 50'th percentile value for the respective fitted distribution,
and U,, and L, are the 99.865 and .135 percentile values, respectively, if the computations are
based on a process width of ±3 times sigma. Note that the values for U, and L, may be different,
if the process width is defined by different sigma limits (e.g., ±2 times sigma). For more on the
use of percentiles see [28].
4.9 Statistical Process Control Plan in an Ideal Setting
Lack of process stability and normal distribution pose serious problems for developing charts
and calculating process performance. The ideal plan summarized in Figure 12, would be to set
the thresholds based on three sigma limits, monitor the process and investigate any points that
fall outside this limit. Once sources are determined, the process can be modified to remove these
sources of variability. The data set can re-evaluated annually to determine the new three sigma
limits and over time the process will improve. Once process stability and a normal distribution
are achieved, process performance can be calculated and used as a metric. This plan meets all the
requirements for statistical process control and will eventually lead to process improvement.
Unfortunately there are some major drawbacks with this plan.
Remove outlying Anually set control
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Figure 12. Process Improvement Cycle
4.9.1 Productivity
Setting the control limits to the three sigma limits would generate a large number of
deviations requiring root cause investigations. Even if the new plan is piloted for one product
campaign and limited to a few processes, the exercise could be quite taxing on the organization.
A new statistical software platform, with more advanced tools, dashboards and collaborative
tools will help but the productivity gains achieved would be erased by all the new root cause
investigations.
4.9.2 Warning with Transforms
One of the problems with the use of transforms when applied to our data is that they tend
to be inconsistent when the time frame is enlarged. If a transform is robust and correctly
describes the underlying distribution, then the transform should not change substantially even
when the time frame is changed. However, for many of the data sets, we found that when the
time frames for a particular attribute changed, the transform was completely different indicating
it is not very robust (that is, it is sensitive to the subtle stability changes in the underlying
process).
4.10 Recommendations
Based on the data collected and literature review, it is felt that normal distribution and
process stability are important for calculating a valid process capability index. However due to
the difficulty in achieving these requirements, there needs to be some flexibility surrounding
these assumptions. This is a compromise we must make to account for the fact that almost no
process that was reviewed met both these requirements. Novartis IQP has in fact agreed to this
change and has issued a new guide chart for instances where one or both assumptions remain
unmet. The guide is a general document for all processes. In the section below, we provide
further recommendations for the three critical parameters reviewed as part of this project.
4.10.1 Content Uniformity
As discussed in Section 4.3, content uniformity is a measure of how consistent a product
is in terms of the percentage of active ingredient. It already has statistical analysis incorporated
and this is why it should not be surprising that it does not follow a normal distribution. In fact,
depending on the target range for CU, the acceptance value for CU is likely to be proportional to
the standard deviation of the samples. Recall,
AV= M - X+ Ks
When we plot the difference between acceptance values (AV) and Ks values as shown in Figure
13, we find the differences to be small. Since Ks is based on the standard deviation, we can
conclude that AV is proportional to standard deviation.
Figure 13. Graph comparing Acceptance Value with Ks
We should also consider the fact that the control limit for acceptance value is 15, and
most of the values we have are considerably lower than this. With this in mind, it is proposed
that in cases where there is no normal distribution or process stability, a simple acceptance chart
should more than suffice for this attribute. An acceptance chart is simply a time series chart that
has horizontal lines displaying the customer specification limits. It is not a control chart since it
simply tells us whether a data point is acceptable (in-specification). Now it is true that an
acceptance chart lacks more sophisticated metrics such as process capability ratios. If we were to
use transforms we could in fact obtain a normal distribution in many cases and calculate process
capability. However, the percentage of cases in which a transformation is successful is not high
enough to justify the endeavor.
4.10.2 Assay
Assay is a key critical parameter and must be monitored closely. In cases where there is
no normal distribution, a transformation is recommended for establishing control three sigma
control limits. The use of Johnson transformations, for example, should be able to produce
normal distributions and therefore allow us to calculate process capability. As with other
processes, the effect of process changes must be monitored to ensure that data sets for different
processes are not combined. Therefore the time series chart may be split into many sub-
segments. In these instances, if the sample data set is too small, we are unlikely to obtain a
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normal distribution required for calculating process capability. Even the proposed IQP guidelines
will not suffice because the distribution may be very far from normal. Therefore in these
instances a run chart will have to suffice for monitoring until enough data is collected for us to
use a transform to obtain normal distribution. Once these limits are established, they do not have
to be recalculated until the process shifts or the control limits are changed.
4.10.3 Dissolution
As can be seen from the dissolution data shown in Figure 14, the discrete levels pose an
issue for achieving a normal distribution. A plot of mean sample values leads to quantization and
makes it virtually impossible to achieve a normal distribution. A plot of all individual data points
solves this first issue.
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Figure 14. Plot of Dissolution Values (Individual Values)
However a chart with individual values (like the one shown in Figure 13) is still unlikely to
reveal a normal distribution. In this case, we would recommend the use of the percentile method
for setting the three sigma control limits. To set the control limits using percentiles, we graph the
data set in the form of a histogram and then calculate the area under the curve and set control
limits equal to the area under the tails of the corresponding three sigma limits. The one
cautionary note here is that since individual values are used (and not sample means) we risk
violating the independence rule. Violating the independence rule may lead to too many false
alarms [13] and if this does occur, the procedure may have to be revised. It should also be noted
that there are other tests that can be performed using individual values. For example, we can
calculate data range values, as well as standard deviation values for each batch (based on the
individual sample values) and use this to measure intra-batch variability. However, for the
purpose of ensuring that dissolution remains above the minimum specification limit, a histogram
using six sigma limits based on the corresponding percentage values will be most useful.
5 Decision Support System
In this chapter we will explore the databases and software packages currently used to generate the
APR/PQR report and the corresponding statistical analysis. After a brief summary of the current
architecture, the chapter focuses on the tools and capabilities needed to automate the report generation
process and increase productivity. Alternate software packages for statistical analysis are evaluated and
the software tool Signal From Noise is recommended as an alternative to Minitab for the automated
system.
5.1 IT Architecture
The current IT architecture for Quality Assurance /Quality Control consists of a myriad of
databases and software packages. Many of these databases are not directly linked, and this makes
data consolidation a time consuming task. In fact in preparation for the APR/PQR, an employee
must first consolidate all relevant data from the different databases into a separate spreadsheet
and then e-mail this spreadsheet to the various parties who will assist in assembling the
document. A few of the relevant databases are listed in Figure 15.
Figure 15. Database description.
Recall the goal of the APR/PQR automation project is to support the creation of the
APR/PQR reports as well as tools for online quality monitoring and trend analysis. This process
involves a number of different steps which are discussed in the subsequent sections.
Database Relevant Information
Chromeleon HPLC QC Data
SAP QM Central Database for QC Data
TEDI Stability Data and recalls
5.1.1 ETL (Extract, Transform, Load)
Extract Transform, Load is the initial operation required to extract data from a database,
perform initial transformations on it if needed, and then store it in a data warehouse. Initially a
data extraction tool must extract the specific data required for a particular APR and store it in the
Data Warehouse (DWH). The extraction tool requires specific data pumps to be programmed
with different databases in order to perform optimally and therefore there is a need to reduce the
number of databases for extraction. As a first step, it is proposed that SAP QM be the central
database for all QC data that is gathered at the QC labs in Stein. This requires building a data
pump from Chromeleon to SAP QM which will eliminate the need for users to manually enter
data which is both cumbersome and time consuming.
5.1.2 Data Warehouse
A data warehouse is defined as "a place where data is stored for archival, analysis and
security purposes" [29]. The idea behind data warehousing is to create a database where all data
from different databases can be consolidated and transformed for further analysis. One might
ask, should SAP QM simply not be made the data warehouse for this system? There are a
number of reasons this solution will not suffice. The APR/PQR report consists of data beyond
that which is stored in SAP for example, drug stability, deviations, batches produced, and drug
complaints data. These data types are kept in separate databases and integrating them into SAP
could be cumbersome. Another important reason for creating a separate data warehouse for QC
data specifically concerns the use of data transformations. In order to maintain data integrity,
SAP QM should store raw data collected from the HPLC tests performed on the lab bench. Later
these values may have to be modified (for example rounded to the nearest integer) before
analysis can be performed on the data. For data integrity reasons it is important that data not be
modified in any manner in SAP QM. Therefore any modification of data should occur after SAP
QM, and a separate warehouse provides an ideal location for this operation. This is why the ETL
operation will be performed between SAP QM and the data warehouse.
Another important parameter that must be determined is the frequency of replication
between SAP QM and the data warehouse. This is highly application specific, but given that lab
tests are generally performed once a day and the lab technicians are only available on day shift,
replication does not need to occur more than once a day. Therefore the data ware house is an
offline data warehouse. In the future if in-line real-time process data is incorporated then the
replication frequency may have to be adjusted.
5.1.3 User Content Management System
The user content management system is responsible for selecting data from the data
warehouse and grouping it into data objects. After creating objects, UCM will import these data
objects into a document management system that will generate the APR/PQR template and fill in
the appropriate fields. The document management system will use Microsoft Word for building
the templates and content formatting. After all the edits of the Word document are complete, the
report will be converted into an Adobe@ PDF file for approval and finally into an electronic
record for submission to health authorities. The process for completing the APR/PQR is
described below.
5.1.4 Workflow Management System
The Workflow Management System (WFMS) handles the lifecycle of the APR/PQR
report. Typically, the reports go through multiple levels of edits and approvals and it is important
that this "workflow" is monitored and secure. The WFMS will first trigger the creation of a
report based on annual reporting cycle for drug registration. The trigger will send an email (or
some other message) to the QA staff member alerting them that a product's APR/PQR report is
now ready to be created. The UCM will automatically generate the Word document and populate
the document with appropriate data objects. Several individuals may collaborate on the report by
working on different chapters. The system will handle the collaborations as well as multiple
versions of the document. Versioning is useful when different collaborators need to check out a
document, make changes or retrieve a previous version of the document. Digital signatures will
be used to handle the approval process and if an edit needs to be made at this stage, the document
will be released back to the collaborators who will edit the document, and resubmit. All changes
will be tracked by the WFMS so that a clear audit trail for the document exists. Once the
approvals are granted at the plant level, the document will be released to the Country Pharma
Organization (CPO) for release of the respective product to the market. Finally the system will
also provide archiving and record management so that reports are easy to search.
5.2 Business Process Intelligence
The various systems described in Section 4.1 together comprise the overall Business
Process Management (BPM) for the APR/PQR generation. What the BPM is missing, is a
method for creating and displaying meaningful analysis from the extracted data. In the IT
industry, this process is termed Business Intelligence (BI). In the APR/PQR scenario, the BI tool
should graph the data, identify trends and point users to critical areas that deserve the most
attention. Since this information is useful to both APR/PQR generation, as well as everyday
quality monitoring, the BI tool should also include a dashboard for general quality tracking. A
dashboard is essentially a web page that uses a number of dials and colors to give users a quick
glimpse of a process and alert users to how well various processes are performing. The data used
to generate the graphs and analysis for the APR/PQR can also be used here to run the algorithms
that monitor quality performance. To satisfy this, the software selected for BI should be flexible
enough to generate graphs and export them to the document management system as well as
display performance metrics on a dashboard. There is some controversy as to whether one tool
can handle both these functions. An alternate approach would be to select one software system
for the APR/PQR, and have a separate one handle the statistical analysis for the dashboard. After
conducting industry research on the various software options available and speaking with a
number of vendors, it appears there are several software packages that can perform both
functions. These software packages are compared with the software currently used for business
intelligence in Section 5.4.
5.2.1 Vision for QA Dashboard
Before software packages are evaluated for the BI platform, the vision and requirements
for the dashboard must be clarified. At a high level, the dashboard must convey information
about how well the manufacturing process is performing from a QA perspective. Users should be
able to view the dashboard and quickly identify critical quality issues that deserve the most
attention. At the same time, the dashboard should also provide information useful for performing
root cause analysis. Finally, the dashboard should be an extension of the APR/PQR Business
Process Management system. The dashboard should allow users to continuously monitor the
same parameters and graphs that will eventually make up the APR/PQR report. This ensures that
issues are detected early and are corrected, instead of waiting till the annual review period is
over. In an ideal scenario, the dashboard should help build a more stable and capable
manufacturing process. In order to do this, a system must be designed that will automatically
make the charts, alert the user to data that violates the predefined rules, and update process
capability in real-time. A potential layout for the dashboard is shown in Figure 16.
Figure 16. Dashboard Hierarchy
The opening layer of the dashboard provides a high level snapshot of the manufacturing
process and identifies deviations that violate user-defined rules. The screen should provide an
easy to grasp visual representation of process capability so that users can immediately identify
which processes need improvement. Color coded dials are one method of representing this
information. Each critical parameter will have a performance dial indicating performance.
Process capability values for various parameters can have pre-defined ranges for red, amber and
green. The diagram in Figure 17 illustrates this.
Figure 17. Dashboard Meter Dial
The dashboard should also provide some detailed information about deviations so that
users know what issues need to be investigated. Issues requiring potential follow-up are
identified based on the statistical rules defined in Chapter 2. An example of this type of
information is provided in Figure 18.
2/3 Drug A CU 3 d consecutive point Out of control limit
2/2 Drug B Assay 9 consecutive point above mean
Figure 18. Example of Dashboard Alerts
The dashboard should also have a method for inputting comments into the system based on
root cause investigations. For example, say a process deviation is investigated and it turns out
that the root cause is a switch in raw material suppliers. The user should be able to input this
comment into the data point associated with the deviation so that anyone else opening the graph
will see that this deviation has already been addressed. Furthermore, these comments should be
stored as objects and imported into the APR/PQR reports along with the graphs. By offering this
feature, the user can simply keep the dashboard open at all times, rather than juggling multiple
databases simultaneously.
5.3 Evaluation of Minitab
The software package currently approved by IQP for statistical analysis at Novartis
Technical Operations is Minitab Version 15. In fact the procedure for performing process
capability analysis of Quality Assurance Data is titled Process Capability Analysis using
Minitab@ Statistical Software. While the software is able to perform the tasks required for
process analysis (distribution chart, calculation of mean, standard deviation, etc.) it does pose
some shortcomings when integrated into an automated IT solution. Minitab is an adequate tool
for detailed statistical analysis in one-off applications, but it lacks many of the capabilities
required for an automated IT solution. In an automated solution, data should automatically be
pulled from SAP QM and analyzed with built in algorithms. The results should be either
displayed on a dashboard or automatically exported to the appropriate APR/PQR report. Minitab
provides connections to other databases using data pumps such as ODBC6 , but once data is
downloaded to the program it cannot be protected. Creating the six pack analysis (required as
part of the SOP for process capability) can be automated using macros, but the displays cannot
be automatically exported to a third party platform. The use of Minitab to build a dashboard is
technically feasible and the support staff at the software vendor mentioned a company that is
using the software in this fashion. However, the example is very complex to implement and
would not serve as an acceptable solution7 . Therefore other software has to be investigated in
order to determine its feasibility for the project.
5.4 Criteria for Statistical Software Selection
Before evaluating alternate software packages, it is important to have a set of criteria.
Based on the requirements of the Global APR/PQR Automation project and the shortcomings
identified with the current Minitab solution, new criteria are required for evaluating competing
software solutions. The quantitative ratings for these criteria are subjective and based on the
features of each software package.
6 Open Database Connectivity (ODBC) provides a standard software interface for accessing database management
systems (DBMS)
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5.4.1 Data Security
Data security refers to the mechanisms for protecting data and ensuring data integrity.
The number of instances that data can be manipulated between the instant the test is performed to
the time of analysis must be minimized. If any changes to the data must be made, these should be
done in the actual database where the data is stored (such as SAP QM) and access to this
database must be restricted. Examples of this include password protection and sum checks. Users
should not have the ability to modify or delete values when importing data from the data
warehousing database into the analysis tool.
5.4.2 Flexibility
Flexibility refers to the number of different tools available within the software package
for statistical analysis. Most packages come with standard features such as run charts, and
histograms. However, more advanced tools may be necessary such as distribution identification,
and transformations. Another highly desired capability is the ability to split a set of data into
stages and display all stages on the same graph. An example of this is shown in Figure 19.
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Figure 19. Example of Run Chart with Split Data Sets
Data may be separated into stages and evaluated for performance separately for a variety
of reasons. One reason could be if a major process change is introduced and this change is
known to impact the measured data (for example by shifting the mean). In this case, the data
after the change should be analyzed separately so that the impact of the change can be accurately
measured and not diluted by the previous data. This feature is vital for analyzing process
performance and measuring the impact of changes.
5.4.3 Automation/User-Friendliness
This automation and user-friendliness category refers to the ease with which tools can be
accessed and the level to which routine analysis can be automated. Minitab, for example, allows
customized macros to be written which helps automate the creation of charts. However, the fact
that the program must be separately opened reduces the level of automation when considering
the statistical software as part of the overall IT solution. Software that can be integrated into a
business intelligence platform seamlessly without the user having to open the software will have
a higher rating.
5.4.4 Validation
All software used for statistical analysis must first be approved by Novartis IQP. This
group will validate the software by performing a number of tests on sample data to ensure that
the results are consistent with the results from approved software platforms. In theory all
professional software tools will eventually be validated. However, some software packages are
already used in other departments at Novartis and these packages will be validated faster.
5.5 Software Review Results
The software packages selected for review are based on industry research, software already
in use by other Novartis subsidiaries and conversations with IQP members who have experience
with statistical tools. Several vendors also provided demos for trial use. The results of the
evaluation are shown in Figure 20.
Data Security Validation Automation/ User Flexibility
Friendly
Minitab 2 3 2 3
IMIS 3 1 3 2
Signal from Noise 3 2 3 3
SAP Business Object 3 2 1 2
StatGraphics 2 2 3 3
OptimProcess 3 2 3 2
Figure 20. Statistical Software Evaluation Results
The numerical ratings are subjective and based purely on how well the software meets the
project criteria. The software vendor that appears to be the best fit for the project is Signal From
Noise (SFN) whose vendor is Lightfoot Solutions Ltd. Interestingly many of these packages are
in trial use with different Novartis divisions. Optim Process is in the testing phase with Novartis
Biologics in Huninge, France while SFN is being tested for use in supply chain and operations in
Stein, Switzerland. IMIS is a software package currently being developed in-house with support
from multiple Novartis sites. Ultimately, SFN provided by Lightfoot Solutions, is the best choice
not only because of the evaluation ratings, but also because many of the data pumps used for
communicating with SAP are already in use for supply chain applications. This thereby reduces
the amount of time for additional programming and ensures that the package will function with
QC data sets.
5.6 Review of Signal From Noise@
Signal From Noise provides the ideal BI platform for both the APR/PQR and the
dashboard. The software contains layers of analysis very similar to the layers described in
Section 4.2.1. The top layer is the actual dashboard made up of multiple dials for tracking the
performance of various parameters. Furthermore, the dashboard can be customized for different
users so that a user only sees the performance dials relevant to them. For example, one dashboard
can be built for tracking products in the solids department while a separate one can be built for
vials and syringes departments. A comprehensive dashboard featuring all dials can be built for
the QA Head.
SFN also provides a variety of SPC charts for graphing various metrics and comparing the
performance of a metric over different periods of time (second layer of the dashboard model). It
allows the user to input a split into a graph if a significant event has occurred, requiring the data
set to be split. The software also allows the user to benchmark a process parameter over different
production units or even different plants. This can be especially useful for Novartis since many
plants produce the same drug and experts may be interested in looking at trends across all plants.
The charts allow the user to click on a data point and enter a comment associated with that point.
These comments are stored on a separate table in the database and can be linked with the objects
for the APR/PQR. SFN provides a key feature concerning the area of data suppression. As
discussed in Chapter 3, data outliers with known root cause determinations should technically be
excluded from process capability calculations. This is because these points are not representative
of the typical process and can skew both the process stability and capability. However, given the
importance of quality data in terms of regulatory compliance, management is very cautious about
suppressing outlying data points even if these points are known to be erroneous. In a regulatory
audit, this could be construed as hiding data from regulators. SFN solves this dilemma by
allowing the user to suppress a data point for calculation purposes, but displaying the data point
in charts. The data point shows up with an asterisk on it, indicating it is suppressed. A comment
will be associated with this asterisk indicating the reason for the suppression and a reference to
the root cause investigation.
Drilling down an additional layer, any data point or data set can be analyzed at the
"transaction" level. This corresponds to the third layer of the dashboard model where the user
can find information about individual data sets such as the date/time stamp, lab equipment
number and many other additional attributes. This information is useful for launching root cause
investigations for deviations. The software allows the user to select a particular data range and
download all the data for this range to an off-line location. This is a powerful feature because the
current method for performing this can take several hours and requires access to multiple
databases. These data sets could be analyzed in detail using more powerful statistical software
such as Minitab.
6 Organizational Implications
The details of the statistical IT platform and the analytical techniques presented in this thesis
alone will not address all the challenges facing Novartis Quality Assurance. To achieve success,
the suggestions must be incorporated into both the overall APR/PQR automation project and
adopted by the various departments within in the company. Accomplishing this requires us to
address some of the strategic, cultural and political challenges within the company.
6.1 Strategic Lens
Novartis is a large pharmaceutical firm with several different divisions. The company has
deliberately not forced standardization across all the divisions and has chosen to operate each
division as if it were a separate company. Corporate management clearly sees some advantages
to this approach including reduced bureaucracy and more flexibility. However, there are some
disadvantages to this approach such as lack of knowledge sharing across divisions and
duplication. Within the Pharmaceutical Operations division there is greater central control
through global standard operating procedures and sharing of information on regulatory
inspections. In the context of this project, Corporate Quality Assurance has allocated funding to
automate the Annual Product Review and make it easier for departments to consolidate and share
data. As described in this thesis there are many mechanisms available for achieving this
automation and it is important that both the end users (in Stein) and corporate share the same
vision for the tool in terms of functionality and application. If not, we run the risk of the tool not
being utilized because the end users fail to see the value in it. This can be avoided by organizing
regular meetings between Novartis IQP members and local QC personnel. Procedures for the
new tool can also be reviewed and refined by applying the existing guidelines and SOPs to actual
data that will be used in an APR/PQR. These meetings will also help tackle scenarios in which
the guidelines fail (such as lack of normal distribution) and help ensure that the delivery of the
new software tool coincides with procedures that are best suited for the data QC reviews on a
continuous basis.
6.2 Cultural Lens
All departments and stakeholders involved with this project share the common goal of
meeting the ICH QIO guidelines and ensuring that the process of producing drugs is
continuously improved. While achieving this vision, the automation project also serves as a
symbol to different stakeholders. For the local QA lab technicians it is a tool that will help
automate data consolidation and allow for more comprehensive data analysis. The technicians
rightfully hope that this tool will make it easier for them to perform their analysis. To the Global
IQP champions, the project represents an opportunity to finally bring statistical process control
concepts and data monitoring to the local site QA departments. There are however some
concerns about the level of automation being incorporated into the final tool. There is some merit
to this concern in that someone still needs to perform the analysis of data sets and some manual
work will still be required. Some have pointed out that regardless of the level of automation
promised through this project, human intuition and analytical rigor is still required to search for
trends and determine their sources. They believe that charts printed on paper and signatures still
hold value in the digital age. While we may not advocate printing all daily individual graphs, the
task of looking at the data and making a digital comment should be incorporated into the daily
responsibilities. Otherwise the daily monitoring tool will sit idle and unused.
The automation tool also brings with it an opportunity for local QA/QC, IQP and
operations to work even more closely on root cause investigations. Many of the lab technicians
have a pharmacy or chemistry background as opposed to IQP champions who tend to be
engineers. Therefore lab technicians are trained in running experiments, and following detailed
procedures, while IQP is perhaps more data driven and accustomed to using analytics to discover
problems and fix them. Both skills are vital for building a culture of continuous improvement,
but in the past collaboration may have been difficult because of the different approaches. This
project, however, should help bring the two groups closer since it will alleviate some of the work
load for QA/QC technicians and allow for greater collaboration.
In Stein, the project is being communicated as a project to automate Minitab analysis and
consolidate data for the APR/PQR. It has been packaged as a project that will both drive
productivity and help QA and production better understand their processes. The Global QA sees
this project as an opportunity to entice the local sites to perform more detailed and frequent
analysis of their data. There is an expectation that the time saved through automation will be
used to do more analysis and drive better process control. This is an important point and more
information around it should be communicated in order to ensure there are no
misunderstandings.
Finally, this tool will should enhance the existing culture of cooperation between local QA
and production. The automated tool will save time and make it easier to quickly display trends.
However, process improvement will only come about through continuous analysis of the data
and determining route causes for excursions. This means production needs to be more involved
with determining the features of this tool and its functionality. The culture in QA also clearly
needs to shift from an organization that performs tests to one that can perform analysis and work
more closely with production. This project is only the first step in that journey.
6.3 Political Lens
It is universally accepted within Novartis that automation and ease of use are paramount to
the success of the project. Where politics can become an issue is in the choice of software
engines for the project. IQP champions have invested time into training the staff at various sites
in the use of Minitab which is specified in the current SOP. The IQP team has written the SOP
for the accepted method of analysis and is therefore considered the authority on statistical
process control for Novartis Pharmaceuticals. This provides the group with a lot of insight over
the direction of the project at Stein, and their buy in with respect to the software platform is
critical for the long term success of the tool.
At the local level the two key stakeholders are the QA department and production.
Currently, all lab results are collected by the QA department and then presented to production.
Deviations are first inspected to rule out lab error and if this is ruled out, a root cause
investigation is opened. Production personnel then take over to determine the connection
between the process and the data point. The automation of data consolidation and statistical
analysis should allow production to see the data points at the same time as QA personnel. This
might lead to production reacting without consulting QA. It is therefore important that the
current method for analyzing data and opening an investigation be reiterated to ensure that there
is no confusion with the new tool.
At the corporate level, the main stakeholder is the Global QA department. They have
tasked IT to help develop the automation of the APR/PQR but who still decide what the tools
should look like and what capabilities it should have. The IQP department also plays an
important advisory role in the statistical analysis portion of the project. While they don't
participate regularly in all project related meetings, their opinion is highly valued in negotiations
about the direction of the project. At the same time it is important that steering committee
members and developers be aware that the end users must be represented as well. We have asked
lab technicians to provide suggestions to be passed on to both the global IT department and the
global IQP group in order to ensure this occurs.
6.4 Conclusion
The three lens analysis above suggests that there are numerous opportunities to ensure long
term success for the implementation of the project. The IQP group is a major stakeholder even
though they may not be directly represented on the project team and their opinion must be
factored into the strategy of the project. The research detailed in this thesis should help bring
about change in both the statistical analysis procedure as well as in the choice of SPC software.
Mindful of this, project leaders should approach the IQP group as well as the steering committee
in advance of any recommendations so that these proposals can be screened for initial support
before the steering committee convenes. It is also equally important to represent the views of lab
technicians and process experts who will be using the tool. Project managers should ensure that
local staff members have reasonable expectations about the level of automation in this new
platform. For continuous monitoring, the graphs and deviations should be automated but in
return this means QA will potentially have more responsibility for follow up. Another area that
requires more attention is bringing local QA leadership and the project team leaders together and
finalizing on the platform and user interface. It is important that senior leadership understand that
the look and feel of the tool is as important as the analysis it performs. Along the same lines
there needs to be a clear explanation of the technical restrictions with the different software
options that have been researched as part of this thesis. Since the steering committee operates at
a very high level, it is important for the project team to present a comprehensive view of the
software choice so that they fully appreciate the challenges with actually integrating an SPC
engine into the automation project. To help with credibility on this front the project team must
include senior technical experts who have experience in software and database projects. Finally,
there should be a demonstration that will allow end users to see the software platform with new
analytical techniques in place.
7 Conclusion and Next Steps
The IT platform for the Decision Support System together with the recommendations
concerning statistical analysis will drastically reduce the time QA personnel spend on data
consolidation and pave the way for better process control. Critical process parameters will be
monitored on a daily basis (rather than annually) and by establishing internal specification at the
six sigma limits (where appropriate), process exceptions will be flagged and investigated. QA
personnel together with process experts will work together in investigating these exceptions and
if a root cause is identified, the data point will be marked and removed from the analysis.
Continuous monitoring will also allow management to assess the process capabilities more
frequently. In terms of the APR/PQR, the system should allow most of the report to be generated
automatically. Process capability plots and run charts can be automatically generated and pasted
into a MS Word document. Since the data will be monitored continuously, there should not be
much time needed to investigate trends and modify the chart before the report is compiled. Data
will be secured in the data warehouse and modification of this data will be restricted to ensure
that the system meets auditing guidelines. The document management system will ensure that
the report has a clear transparent audit trail with no loss of data. It will also ensure that the report
remains in a secure database instead of versions of the report being transmitted via e-mail. The
systems will also be scalable, which is important since this system may be deployed to multiple
Novartis sites.
In terms of next steps, the IT system needs to be developed by the project management
team and piloted at Stein or another Novartis Pharmaceutical manufacturing location. Staff
should be trained to use the new system and a few products should be piloted for continuous
monitoring. Dashboard templates should also be customized for the various end users who will
be using the dashboard. One aspect of this project that must not be overlooked is the need for
awareness and support. The success of this tool depends on users having access to all the features
incorporated into the product as well as an efficient organizational framework to go with it.
Management must decide how QA and production will collaborate to investigate exceptions and
when internal OOE limits must be changed. There also needs to be clear communication between
the two departments to ensure that process changes are communicated to the QA personnel who
will be monitoring the data. With the right organizational incentives and the appropriate training,
the new system should ensure improved process performance as well as higher productivity for
the QA department. It is also in-line with the FDA's desire for "A maximally efficient, agile,
flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products
without extensive regulatory oversight" [32].
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